Dulaglutide (Trulicity) (with Lilly)
Type 2 Diabetes
Key Facts
About Halozyme Therapeutics
Halozyme Therapeutics has established itself as a dominant force in subcutaneous drug delivery through its validated ENHANZE® technology platform. The company's strategy successfully combines high-margin royalty and milestone revenue from over a dozen partnerships with leading pharma companies (including Roche, Takeda, and Pfizer) with direct sales from its commercial products, HYLENEX® and XYOSTED®. This dual business model provides diversified revenue streams and leverages a single, scalable platform technology to reduce treatment burden and improve patient outcomes across multiple therapeutic areas. Halozyme's commercial validation and expanding partnership pipeline position it for sustained growth as the industry shifts towards convenient, patient-centric administration.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |